Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors / 国际肿瘤学杂志
Journal of International Oncology
; (12): 180-183, 2021.
Article
en Zh
| WPRIM
| ID: wpr-882529
Biblioteca responsable:
WPRO
ABSTRACT
Poly ADP-ribose polymerase(PARP)inhibitor is a targeted biological agent for the treatment of ovarian cancer, which is mainly suitable for platinum-sensitive ovarian cancer patients. However, data from clinical trials showed that PARP inhibitors have certain therapeutic effect on platinum-resistant or platinum-refractory ovarian cancer patients. It may become a new hope for treatment of ovarian cancer patients in the future.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of International Oncology
Año:
2021
Tipo del documento:
Article